#Drug Testing Market Growth

[industryforecastnews]

Drug Testing Market Size To Reach USD 8.45 Billion By 2030

Drug Testing Market Growth & Trends

The global drug testing market size is expected to reach USD 8.45 billion by 2030, expanding at a CAGR of 4.8% from 2024 to 2030, according to a new report by Grand View Research, Inc.. The introduction of innovative tests, stringent regulation mandating drug testing, and growing substance abuse & addiction are some of the factors anticipated to foster market growth during the forecast period. 

Drug abuse and addiction is a global problem, affecting millions of people. As per the World Drug Report published by UNODC, in 2019, around 35.0 million people were suffering from drug use disorders globally. Such a high rate of drug abuse and substance use disorders has created a major demand for innovative tests to prevent, treat, and manage such cases. Several key players operating in this space are introducing innovative and efficient products to meet this growing demand.

For instance, in June 2019, Quidel Corporation received the U.S. FDA’s 510(k) clearance to market its fluorescence immunoassay—Quidel Triage TOX Drug Screen, 94600. This is intended for detecting the presence of metabolites or drugs in urine. Moreover, in June 2020, Cordant Health Solutions offered video-observed oral fluid drug testing to help courts & government agencies to monitor participants during the COVID-19 pandemic. This aided in combating several challenges faced by people with substance abuse disorders during the pandemic.

Continuous government initiatives and implementation of strict substance abuse testing regulations to ensure safety have derived the demand for its testing products. In July 2020, the New Zealand government introduced a new bill that provides police the power to conduct random roadside drug testing of drivers to reduce impaired driving in the country. The new bill allows usage of oral fluid tests to check drivers for substances such as cocaine, ecstasy, cannabis, opiates, methamphetamine, and benzodiazepines. Also, in February 2020, the Directorate General of Civil Aviation in India introduced extensive tests for pilots and flight crew members for psychoactive substances such as opioids & cannabis to ensure safe air travel.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/drug-testing-market

Drug Testing Market Report Highlights

By product type, the consumables segment dominated the market in 2023, owing to its repetitive use to conduct substance abuse screening

Based on sample type, the urine samples segment accounted for the largest revenue share in 2023, as it is the most common method of sample collection

Increased unemployment and economic crisis due to the Covid-19 pandemic has made people more susceptible to substance abuse, thus created lucrative opportunities in the market

The legalization of marijuana for medicinal as well as recreational use in several countries is anticipated to change the current scenario and may create demand for innovative testing solutions

Stringent privacy rights in some countries are likely to limit substance abuse testing at workplaces, impeding market growth

In Asia Pacific, the market is expected to witness lucrative growth over the forecast period as a result of the growing demand for substance abuse testing from emerging economies, such as China and India

Drug Testing Market Segmentation

Grand View Research has segmented the global drug testing market based on product, sample, drug, end-use, and region:

Drug Testing Product Outlook (Revenue, USD Million, 2018 - 2030)

Consumables

Instruments

Rapid Testing Devices

Services

Drug Testing Sample Outlook (Revenue, USD Million, 2018 - 2030)

Urine Samples

Oral Fluid Samples

Hair Samples

Other Samples

Drug Testing Drug Outlook (Revenue, USD Million, 2018 - 2030)

Alcohol

Cannabis/Marijuana

Cocaine

Opioids

Amphetamine & Methamphetamine

LSD

Others

Drug Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)

Drug Testing Laboratories

Workplaces

Hospitals

Others

Drug Testing Regional Outlook (Revenue in USD Million, 2018 - 2030)

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Regional Insights

North America drug testing market dominated and accounted for a 39.5% share in 2023. This high share is attributable to the local presence of key global market players, such as Bio-Rad Laboratories, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd. and others. Moreover, the growth of the drug testing market in North America can majorly be attributed to the increasing incidence of abuse, stringent government regulations, and active screening programs. The governments are actively engaged in controlling the consumption of hazardous drugs to minimize the cost burden associated with it. In addition, the authorities are focusing on formulating new policies. For instance, in September 2023, San Francisco Human Services Agency (SFHSA) announced a new initiative that would need people suffering from substance use disorder who wish to gain access to county funds to enroll in treatment and services.

List of Key Players in Drug Testing Market

Quest Diagnostics Incorporated

Abbott

F. Hoffmann-La Roche Ltd.

Quidel Corporation

Thermo Fisher Scientific, Inc.

Siemens Healthcare GmbH

Bio-Rad Laboratories, Inc.

Agilent Technologies, Inc.

Laboratory Corporation of America Holdings

Clinical Reference Laboratory, Inc.

Cordant Health Solutions

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/drug-testing-market  

[medicaldevicesindustrynews]

Rising Consumption of Illicit Drugs Boost Demand for Drug Abuse Testing

Rising Consumption of Illicit Drugs Boost Demand for Drug Abuse Testing

Drug abuse is defined as the deliberate consumption of illegal drugs or prescribed psychoactive involvement, or non-therapeutic performance enhancer drug for non-medicinal effects. The strong addiction may cause an irresistible, uncontrollable, and compulsive desire for its intake.  The majorly consumed drugs of abuse are cannabinoids, opiates, cocaine, LSD, barbiturates, alcohol, amphetamines,…

[mitalipingale]

The Sports Drug Testing Market in 2023 is US$ 17.74 billion, and is expected to reach US$ 65.42 billion by 2031 at a CAGR of 17.7%.

[jangillman]

President Trump's Achievements

Hey!! What has Donald Trump done while he was in office (as at July, 2017)!!!

1.Supreme Court Judge Gorsuch

2.59 missiles dropped in Syria.

3.He took us out of TPP

4.Illegal immigration is now down 70%( the lowest in 17 years)

5.Consumer confidence highest since 2000 at index125.6

6.Mortgage applications for new homes rise to a 7 year high.

7.Arranged 20% Tariff on soft lumber from Canada.

8.Bids for border wall are well underway.

9.Pulled out of the lopsided Paris accord.

10.Keystone pipeline approved.

11.NATO allies boost spending by 4.3%

12.Allowing VA to terminate bad employees.

13.Allowing private healthcare choices for veterans.

14.More than 600,000. Jobs created

15. Median household income at a 7 year high.

16. The Stock Market is at the highest ever In its history.

17. China agreed to American import of beef.

18. $89 Billion saved in regulation rollbacks.

19. Rollback of A Regulation to boost coal mining.

20. MOAB for ISIS

21. Travel ban reinstated.

22. Executive order for religious freedom.

23. Jump started NASA

24. $600 million cut from UN peacekeeping budget.

25. Targeting of MS13 gangs

26. Deporting violent illegal immigrants.

27. Signed 41 bills to date

28. Created a commission on child trafficking

29. Created a commission on voter fraud

30. Created a commission for opioids addiction.

31. Giving power to states to drug test unemployment recipients.

32. Unemployment lowest since may 2007.

33. Historic Black College University initiative

34. Women In Entrepreneurship Act

35. Created an office or illegal immigrant crime victims.

36. Reversed Dodd-Frank

37. Repealed DOT ruling which would have taken power away from local governments for infrastructure planning

38. Order to stop crime against law enforcement.

39. End of DAPA program.

40. Stopped companies from moving out of America.

41. Promoted businesses to create American Jobs.

42. Encouraged country to once again

43. 'Buy American and hire American

44. Cutting regulations 2 for every one created.

45. Review of all trade agreements to make sure they are America first.

46. Apprentice program

47. Highest manufacturing surge in 3 years.

48 $78 Billion promised reinvestment from major businesses like Exxon, Bayer, Apple, SoftBank, Toyota...

49. Denied FBI a new building.

50. $700 million saved with F-35 renegotiation.

51. Saves $22 million by reducing white house payroll.

52. Dept of treasury reports a $182 billion surplus for April 2017

(2nd largest in history.

53. Negotiated the release of 6 US humanitarian workers held captive in egypt.

54. Gas prices lowest in more than 12 years.

55. Signed An Executive Order To Promote Energy Independence And Economic Growth

56. Has already accomplished more to stop government interference into people's lives than any President in the history of America.

57. President Trump has worked with Congress to pass more legislation in his first 100 days than any President since Truman.

58. Has given head executive of each branches 6 month time Frame dated march 15 2017, to trim the fat. restructure and improve efficacy of their branch.

Observe the pushback the leaks the lies as entrenched POWER refuses to go silently into that good night!

I hope each and every one of you copy and paste this everywhere, every time you hear some dim wit say Trump hadn't done a thing!

THANK YOU!!!

Oh, yeah, and there's this..........

[dreaminginthedeepsouth]

Steve Brodner

* * * *

The city of Springfield, Ohio, has been thrust into the national spotlight by the racist slurs of Donald Trump and JD Vance directed at the city’s Haitian immigrant population. Springfield matters on many levels: It represents a city struggling to overcome the collapse of the Midwest manufacturing base that served as the driver of America’s economy in the last century. Those struggles include population flight, high levels of poverty, low levels of education, weak housing markets, and stress on social systems and infrastructure caused by foreign immigration.

Springfield is like hundreds of cities across the nation struggling with the same issues. Springfield matters because its citizens have not given up. They are fighting to reclaim and renew their historic city. They are doing so by revitalizing the city’s manufacturing base, focusing on aerospace, technology, agriculture, and distribution logistics. Springfield leaders are attempting to revitalize the downtown business district by creating a business-friendly environment. Springfield is welcoming new residents, including immigrants, by expanding housing stock and recruiting workers to its renewed industrial base.

The challenges facing the leaders and residents of Springfield are daunting and the solutions are multifaceted. But one essential element of Springfield’s future is foreign immigration. Without it, Springfield’s path to renewal will be much more difficult. Indeed, Springfield’s two centuries of growth were fueled by successive waves of immigrants from Germany, Italy, and Ireland.

Each of those waves of immigration brought growing pains, including racial tension and violence. Springfield is now experiencing a new wave of immigration—this time from Haiti. As Springfield city managers acknowledge, the most recent wave of immigration is stressing city resources, but they are actively working on solutions.

Before turning to the commendable response by the Springfield city managers, it is worth noting the degree to which population flight has defined the city’s current crisis and how foreign immigration offers a potential path forward.

The chart [at link] shows the population trend in Springfield, Ohio from 1960 through 2020 (as documented by the US Census Bureau):

Over fifty years, Springfield lost nearly 30% of its population. The population decrease had cascading effects on business activity, education, personal wealth, and tax revenues. (Of course, the population decrease is also a product of the collapse of the mid-century industrial base.)

Based on the Census Bureau profile of Springfield, Ohio for 2020, the city faces the following challenges:

A poverty rate double the national average (22% vs. 11%).

An employment rate of 53.1% vs a national rate of 60%.

A population that lags in college degrees (bachelor’s and beyond) 15% vs  50%.

3,000 vacant housing units—an 11% vacancy rate vs an 8% vacancy rate in surrounding Clark County.

A depressed housing market, with median prices of $175,000 in Springfield vs $231,000 in Ohio vs $412,000 nationally

The US Census report linked above shows some people in their 30s and 40s move away from Springfield—creating labor shortages in the prime working years for adults. See NPR (9/19/2016), Springfield, Ohio: A Shrinking City Faces A Tough Economic Future. Per NPR,

Median incomes fell an astounding 27 percent in Springfield between 1999 and 2014, more than any metropolitan area in the country, according to the Pew Research Center.

The labor flight was exacerbated by the opioid crisis. Per NPR, “Employers say it's gotten harder to find job applicants who can pass a drug test.”

The above challenges are daunting and require a multi-pronged approach. But one thing is clear: Springfield cannot “shrink” its way to prosperity and renewal. It must grow its population to increase its labor and tax base to support increased economic activity.

Fifty years of population declines show that Springfield will not attract residents from Ohio or other states to fuel its growth. In 2020, Haitian immigrants began moving into Springfield for employment. Over the last four years, 12,000 to 15,000 Haitian immigrants moved to Springfield under the Immigration Parole Program. After arriving in Springfield, they applied for Temporary Protected Status (TPS), allowing them to legally live and work in the US.

Adding 15,000 people in four years to a population base of 58,000 is challenging and has impacted Springfield’s social services and infrastructure. But city managers have been welcoming of the new immigrants. See Immigration FAQs | City of Springfield Ohio Official Website.

The city website addresses immigration, in part, as follows:

Community leaders and agencies are working collaboratively to provide programs and solutions to acclimate our new immigrant community and to protect our entire population of Springfield. Some initiatives already executed include: English language classes, driving courses, cultural awareness, banking and home ownership, work opportunities and healthcare. City leaders are also working with state and federal legislators in an effort to get the increased funding necessary to ensure continued public and sustainable for all of our citizens in our community.

Springfield’s City Manager, Bryan Heck, published a video on September 12, 2024. I urge you to take four minutes to listen to Heck, who not only debunks the rumors being spread by Trump and Vance but puts forth a positive case for Springfield’s renewal. See YouTube, Bryan Heck | Springfield city manager addresses false claims

Springfield’s leaders' efforts to revitalize the city’s business base while welcoming new residents, including immigrants, are exemplary, and they deserve praise and support for their efforts.

Instead, Trump and JD Vance have poured gasoline onto an already challenging situation and lit a match by spreading racist and defamatory rumors directed at the Haitian community in Springfield. Their lies have flamed animosity and resentment from some residents of Springfield to an immigrant population that they blame for Springfield’s woes—problems that predated the surge of immigration in 2020. Indeed, as I hope I have made clear, the Haitian immigrant community in Springfield is part of the city’s path to recovery and renewal.

On Thursday, someone called in bomb threats to city hall in Springfield—with the threat using “hateful language” about Haitian immigrants. The threat caused city officials to close schools in the area. See The Guardian, Bomb threat shuts down Ohio city hall after Trump spreads baseless migrants rumor.

Springfield’s mayor and police chief, as well as Ohio Governor Mike DeWine, have criticized Trump and Vance's comments.

So, here we are: A city in Ohio that is doing its best to accomplish an economic renewal that necessarily involves a labor force immigrating into the city finds itself used as a campaign prop by politicians who have no interest in helping Springfield. Instead, the politicians are making it harder for city leaders to manage a challenging situation.

Springfield, Ohio, matters because it represents hundreds of US cities struggling with the same problems. It matters because its leaders and residents haven’t given up. It matters because its leaders and most of its residents have welcomed the Haitian immigrant community and are doing their best to manage their way through the strains caused by a 25% spike in population in four years.

America is a great nation because of immigration. America will continue to be a great nation, in part because of immigration. Yes, the immigration system is broken. But don’t confuse that dysfunction with the energy, talent, and vision re-injected into America with each successive wave of immigrants pursuing the same dream that our ancestors followed to our shores.

What is so pernicious and vile about the comments by Trump and Vance is that they are not attacking the broken immigration system. They are attacking and stigmatizing immigrants themselves, claiming that they are “poisoning” the blood of Americans—a fanciful conceit because the “blood” of Americans is a mixture of every race and ethnicity on Earth.

By falsely claiming that Haitians are eating the household pets of residents in Springfield, Trump and Vance seek to cast Haitians as “others” who are inferior to “real Americans”—defined as immigrants who had the good fortune to arrive in America in an earlier wave of immigration.

If there is a silver lining to the unvarnished ugliness of the rumors being spread by Trump and Vance, it is that they are doubling down on fictions that almost no one believes. The press is on the scent, looking to disprove their vile lies. The more that Trump and Vance repeat them, the more hateful and just plain weird they look.

The Trump-friendly Politico reported on Trump's inability to leave the topic alone in his first appearance after the debate. See Politico, Trump got back on track with the border. Then he started talking about the dogs (and geese).

Per Politico,

For a moment, it seemed like Donald Trump was using his Tucson, Arizona, rally to return to his typical immigration programming after a shaky debate performance. Then he went there — again. Trump repeated the baseless claim that Haitian migrants are eating pets in Springfield, Ohio — remarks that became the stuff of endless social media memes soon after his debate.  [¶¶] But after two days of unflattering headlines and Republicans squabbling over him pushing an anti-immigrant conspiracy theory, Trump once again couldn’t resist veering off into the outrageous.

Meanwhile, Kamala Harris was in North Carolina knocking the ball out the park (again) before a packed rally. See The Guardian, Harris touts strong debate performance as Trump says he won’t face her again.

A video of Harris’s first speech in North Carolina is here, Kamala Harris full speech at Charlotte, NC rally (Sept. 12, 2024). I have the video cued to start at Harris’s challenge to Trump to hold a second debate.

Harris’s body language, facial expessions, and obvious happiness speak volumes about her growing confidence. Although much of the substance of her speech in NC is familiar, her interactions with the crowd and her delivery are improving. Check out a few minutes of the speech if you haven’t seen it. She is a natural and effective campaigner!

[Robert B. Hubbell Newsletter]

[highfantasy-soul]

Re: Netflix's live-action Avatar the Last Airbender

I was 12 when the animated series started airing.

I caught episodes as they came on Nickelodeon, but I didn’t watch it religiously start-to-finish. I caught episodes when they happened to be on and I happened to be watching TV (I was NOT part of the generation that had unlimited access to shows - tv/computer/video game time was strictly monitored in my household) so there were some episodes I saw over and over again, and others I never did see.

I think it was around middle/high school (honestly can't remember - it was one of the two) that the show got put on Netflix and I started watching it from the beginning with my brother and some friends. Needless to say, I've been a die-hard fan ever since.

I think the animated show is incredibly well done and the storytelling is super on-point for what I love in media. Zuko's redemption arc is still the best arc I've ever seen, and the character growth is amazing.

I had never really fallen into the 'it's not perfect, but…' way of analyzing media, so I never dwelt too much on its flaws - I'd much rather focus on the things it got right as literally every piece of media has flaws and things that could be changed to make it better.

So yeah, hyperbolically, the animated version of ATLA is 'perfect' - but since people insist on anything that's not perfect being drug through the mud and hyperbolically being called 'garbage', I guess I have to dredge up the things I didn't care so much for in the animated version while analyzing how the live-action handled it (or avoided handling it).

I was super excited for the film adaptation - again, announced while I was in high school. I was looking forward to it so much - then, well, we know what happened there.

Things were changed that didn't make sense to change (the pronunciation of character names, the 'test' for figuring out who the Avatar is, the poor bending where movements didn't align to what was happening with the CGI, casting of white people when the characters were always meant to be indigenous and all asian ethnicities, among other issues people have made many essays about)

So, when this was first announced, I was SKEPTICAL.

While the trailer looked good, it seemed very safe - I recognized everything in it and it looked well made, but like, that doesn't mean the whole thing will be good - or justify its existence.

I tried to ignore any 'leaks' or interview quotes because those are always misconstrued so much and people hear one sentence and create a massive narrative in their head about what that sentence means and usually, all their bellyaching assumptions they made from that piece of info is just a non-issue once the show actually comes out.

I didn't give any credence to people screaming about "Sokka isn't going to be sexist anymore?? It's ruined!!" or "They're going for a Game of Thrones tone?? They don't understand Avatar at all!!" or "No side-quests?? They don't understand the point of the show!!"

First off, invoking the demon that is Game of Thrones is just a marketing tactic - that's all it is: MARKETING!! Just like EVERY YA book for years was 'The new Hunger Games' now it's 'The new Game of Thrones' even when the story at hand is NOTHING AT ALL LIKE THOSE THINGS!! It's literally, let me cradle your face gently in my hands, JUST a marketing ploy to get you to see a recent title you DO recognize and have (assumedly) heard good things about (ie popular) so that you then pick up the thing that they slapped that name onto.

Creators rarely have say in what their creation is likened to, they're told by marketing companies to go with it (if they're told anything at all) and they just say "yes, marketing team I have no control over, whatever you say".

Also, a passing comment in an interview is off-the cuff and when someone makes a comment like that, people read WAY too far into it and it's usually not nearly as deep as people make it out to be. That's why I just wait for the actual thing to come out and just watch it and judge it based on what it is, not some narrative someone else has created for it based on half a quote from some random interview.

So going into this: why the live-action adaptation? Why was it necessary?

In my opinion, the answer to this question is the thing many fans hate the most: altering the original story.

A beat-for-beat remake isn't necessary - the original is right there, so in order to 'earn' the right for this adaptation to exist, that necessitates changes to be made that add to the themes, deepen the lore, and delve into different aspects of the world in ways a child's cartoon can't.

So, I'm looking for not a 1-1 remake, but rather an adaptation that enhances the themes, irons out some uneven characterization/pacing, updates the story just enough to really get what they want to across, and delve more directly into some of the harsher aspects of the war.

I have always felt that Iroh's involvement in the Fire Nation military was glossed over a lot in the cartoon - I suspect because he's supposed to be a good guy and we can't have our good guys be overtly war criminals responsible for the deaths of thousands of people.

The effects of hard decisions made during war are shown in the animation, but the decision making process itself is rarely talked about until the very end with the gaang's struggle to keep helping people while also knowing where to focus their energy and Aang's struggle finding a way to stop the firelord without killing him.

something this adaptation can do is actually show the people making the decisions - and directly talking about the horrible effects of it. I'll get to it later, but that's one of the major themes in Episode 4 that I'll talk more on then.

Especially in Book 1, like many first books/seasons, the worldbuilding isn't fully fleshed out and the themes that really come to fruition later aren't as tight as they could be at the beginning. If the adaptation can go ahead and seed/tighten the themes that become big deals later on here at the beginning, it will 'justify' it's existence as the story retold after the whole story has already been plotted out.

Just like with the Percy Jackson and Wheel of Time adaptation, those writing for the show have the benefit of knowing how the story ends and all the stuff that's added to the world building as time goes on that wasn't necessarily known by the authors when they wrote and published the first books - the benefit of hindsight allows the show's script to take into consideration these additions and seed them early on to make the story more cohesive and reinforce themes.

So, this analysis is going to be long and filled with minute details, beat by beat for the episodes.

I have seen so many takes that I just sit and scratch my head at and think 'that was so obvious in the show - how did you miss/misinterpret that thing so wildly?' that I guess what I took for granted as obvious in the show, others didn't, so here's me being pedantic and over-explaining everything so maybe others can see that 1) they aren't the only ones who saw this interpretation and 2) maybe others will see the scenes a different way

Still trying to decide how to break up the analysis as the episode recaps are going to be LONG and since people now demand to see all the citations for stuff, the character analysis posts will be long too as I pull direct scenes to show why I feel the way I do.

I don't want to overload the posts and make it so they're just annoying to read, so I'll probably break them up into the sections of the episodes and maybe break up the character posts.

[Masterlist of my NATLA thoughts]

[elsa16744]

Big Data and AI: The Perfect Partnership for Future Innovations 

Innovation allows organizations to excel at differentiation, boosting competitive advantages. Amid the growth of industry-disrupting technologies, big data analytics and artificial intelligence (AI) professionals want to support brands seeking bold design, delivery, and functionality ideas. This post discusses the importance of big data and AI, explaining why they matter to future innovations and business development. 

Understanding Big Data and AI 

Big data is a vast data volume, and you will find mixed data structures because of continuous data collection involving multimedia data objects. A data object or asset can be a document, an audio track, a video clip, a photo, or identical objects with special file formats. Since big data services focus on sorting and exploring data objects’ attributes at an unprecedented scale, integrating AI tools is essential. 

Artificial intelligence helps computers simulate human-like thinking and idea synthesis capabilities. Most AI ecosystems leverage advanced statistical methods and machine learning models. Their developers train the AI tools to develop and document high-quality insights by processing unstructured and semi-structured data objects. 

As a result, the scope of big data broadens if you add AI integrations that can determine data context. Businesses can generate new ideas instead of recombining recorded data or automatically filter data via AI-assisted quality assurances. 

Why Are Big Data and AI Perfect for Future Innovations? 

1| They Accelerate Scientific Studies  

Material sciences, green technology projects, and rare disorder research projects have provided humans with exceptional lifestyle improvements. However, as markets mature, commoditization becomes inevitable. 

At the same time, new, untested ideas can fail, attracting regulators’ dismay, disrespecting consumers’ beliefs, or hurting the environment. Additionally, bold ideas must not alienate consumers due to inherent complexity. Therefore, private sector stakeholders must employ scientific methods to identify feasible, sustainable, and consumer-friendly product ideas for brand differentiation.  

AI-powered platforms and business analytics solutions help global corporations immediately acquire, filter, and document data assets for independent research projects. For instance, a pharmaceutical firm can use them during clinical drug formulations and trials, while a car manufacturer might discover efficient production tactics using AI and big data. 

2| Brands Can Objectively Evaluate Forward-Thinking Business Ideas 

Some business ideas that a few people thought were laughable or unrealistic a few decades ago have forced many brands and professionals to abandon conventional strategies. Consider how streaming platforms’ founders affected theatrical film releases. They have reduced the importance of box office revenues while increasing independent artists’ discoverability. 

Likewise, exploring real estate investment opportunities on a tiny mobile or ordering clothes online were bizarre practices, according to many non-believers. They also predicted socializing through virtual reality (VR) avatars inside a computer-generated three-dimensional space would attract only the tech-savvy young adults. 

Today, customers and investors who underestimated those innovations prefer religiously studying how disrupting startups perform. Brands care less about losing money than missing an opportunity to be a first mover for a niche consumer base. Similarly, rejecting an idea without testing it at least a few times has become a taboo. 

Nobody can be 100% sure which innovation will gain global momentum, but AI and big data might provide relevant hints. These technologies are best for conducting unlimited scenario analyses and testing ideas likely to satisfy tomorrow’s customer expectations. 

3| AI-Assisted Insight Explorations Gamifies Idea Synthesis 

Combining a few ideas is easy but finding meaningful and profitable ideas by sorting the best ones is daunting. Innovative individuals must embrace AI recommendations to reduce time spent on brainstorming, product repurposing, and multidisciplinary collaborations. Furthermore, they can challenge themselves to find ideas better than an AI tool. 

Gamification of brainstorming will facilitate a healthy pursuit of novel product features, marketing strategies, and customer journey personalization. Additionally, incentivizing employees to leverage AI and big data to experiment with designing methods provides unique insights for future innovations. 

4| You Can Optimize Supply Chain Components with Big Data and AI Programs 

AI can capture extensive data on supply chains and offer suggestions on alternative supplier relations. Therefore, businesses will revise supply and delivery planning to overcome the flaws in current practices. 

For instance, Gartner awarded Beijing’s JD.com the Technology Innovation Award in 2024 because they combined statistical forecasting. The awardee has developed an explainable artificial intelligence to enhance its supply chain. Other finalists in this award category were Google, Cisco, MTN Group, and Allina Health. 

5| Academia Can Embrace Adaptive Learning and Psychological Well-Being 

Communication barriers and trying to force all learners to follow the standard course material based on a fixed schedule have undermined educational institutions’ goals worldwide. Understandably, expecting teachers to customize courses and multimedia assets for each student is impractical and humanly infeasible. 

As a result, investors, policymakers, parents, and student bodies seek outcome-oriented educational innovations powered by AI and big data for a learner-friendly, inclusive future. For instance, some edtech providers use AI computer-aided learning and teaching ecosystems leveraging videoconferencing, curriculum personalization, and psycho-cognitive support. 

Adaptive learning applications build student profiles and segments like marketers’ consumer categorizations. Their AI integrations can determine the ideal pace for teaching, whether a student exhibits learning disabilities, and whether a college or school has adequate resources. 

Challenges in Promoting Innovations Based on Big Data and AI Use Cases 

Encouraging stakeholders to acknowledge the need for big data and AI might be challenging. After all, uninformed stakeholders are likely to distrust tech-enabled lifestyle changes. Therefore, increasing AI awareness and educating everyone on data ethics are essential. 

In some regions, the IT or network infrastructure necessary for big data is unavailable or prone to stability flaws. This issue requires more investments and talented data specialists to leverage AI tools or conduct predictive analyses. 

Today’s legal frameworks lack provisions for regulating AI, big data, and scenario analytics. So, brands are unsure whether expanding data scope will get public administrators’ approvals. Lawmakers must find a balanced approach to enable AI-powered big data innovations without neglecting consumer rights or “privacy by design” principles. 

Conclusion 

The future of enterprise, institutional, and policy innovations lies in responsible technology implementations. Despite the obstacles, AI enthusiasts are optimistic that more stakeholders will admire the potential of new, disruptive technologies. 

Remember, gamifying how your team finds new ideas or predicting the actual potential of a business model necessitates AI’s predictive insights. At the same time, big data will offer broader perspectives on global supply chains and how to optimize a company’s policies. 

Lastly, academic improvements and scientific research are integral to developing sustainable products, accomplishing educational objectives, and responding to global crises. As a result, the informed stakeholders agree that AI and big data are perfect for shaping future innovations.  

[mariacallous]

There’s a well-established inverse relationship between a dog’s size and its expected lifespan. Bernese mountain dogs and Great Danes live just six to eight years, for example, while corgis can live up to 15 years and Chihuahuas up to two decades.

San Francisco biotech company Loyal wants to close that gap, and is developing an experimental drug to extend the lifespan and improve the quality of life of large and giant dog breeds. Today, the company announced that based on early data, the US Food and Drug Administration has determined that Loyal’s drug has a “reasonable expectation of effectiveness.” The company hasn’t yet shown that its drug actually extends lifespan, but the FDA decision signals the agency’s confidence in Loyal’s approach, and the drug will soon be tested in a bigger trial.

“Big dog owners want more time with their dogs,” says Loyal CEO Celine Halioua. “It’s really heartbreaking to people that they don’t live that long.” She argues that the wide variety in dog sizes isn’t natural, but a result of selective breeding by humans to create dogs with certain physical traits or that can perform specific tasks. On average, mixed-breed dogs live longer than their purebred counterparts.

So far, the FDA has not approved any drugs to expand the lifespan of animals—or humans, for that matter. “This is completely novel,” says Linda Rhodes, former CEO of pet biotech company Aratana Therapeutics and a consultant for Loyal. It’s difficult to study life-extension drugs in people, she says, because humans live relatively longer lives than other species. But starting with dogs—and the breeds with the shortest lives—could yield important clues. “The implication for other species, including humans, is pretty profound,” she says.

Loyal’s experimental drug is an injection designed to be given every three to six months by a veterinarian. The drug is meant to lower levels of a hormone called IGF-1, which is involved in growth and metabolism and has been linked to dog size. Large dogs have a genetic variant that leads to high levels of IGF-1 and small dogs have a different variant that results in lower levels.

Inhibiting this hormone has been shown to increase lifespan in worms, flies, and rodents. In humans, both very high and very low levels increase mortality risk, while a midrange is associated with the lowest mortality.

In early studies, Loyal dosed 130 research dogs with its investigational drug. Halioua says the company has shown that it can reduce IGF-1 levels in large dogs to those seen in medium-size dogs. Two dogs had loose stools for a day or two after receiving the injection, but beyond that, Halioua says, no major side effects have been observed.

To determine the drug’s effect on lifespan, the company is planning a bigger study that will start in 2024 or 2025, and enroll about 1,000 large and giant breed companion dogs that are at least 7 years old. Each will receive either the experimental drug or a placebo.

Halioua says the company aims to have its drug on the market by 2026. But first, Loyal still has to prove to the FDA—which regulates both human and veterinary medicines—that the injection is safe and that the drug can be reliably manufactured. At that point, the FDA can grant conditional approval, a temporary authorization that lasts five years and allows the drug to be sold by prescription. During that time, Loyal will collect effectiveness data and apply for full approval.

Loyal is also working on two other drugs: a pill version for large and giant dog breeds, and a pill for older dogs of all breeds.

Danika Bannasch, a veterinary geneticist at the University of California, Davis, who specializes in canine genetics, says that IGF-1 is only one factor thought to be associated with dog size and longevity. “As for targeting it, I think it’s a bit premature. We know that smaller breed dogs live longer than larger breed dogs, but we don’t know how much of that is due to the influence of IGF-1,” she says.

In a study published last month, Bannasch and her colleagues identified another possible driver of dog longevity, a gene called ERBB4. Studying more than 300 golden retrievers, they compared the DNA from blood samples of dogs that were still alive at 14 years of age to those that died before age 12. They found that dogs with certain variants of the gene survived longer—on average, 13.5 years compared to 11.6 years. Bannasch cautions that the work was conducted in only one breed and that it’s not known whether these variants are associated with longer life in other types of dogs.

The ERBB4 gene is the canine version of HER4, a human gene closely related to HER2, which is associated with cancer. Studying the canine gene could have implications for human health. Researchers are also testing new cancer treatments in dogs with the hope that these therapies could help people.

Giving an experimental drug to healthy dogs is different from treating sick dogs. Bannasch says Loyal’s drug will need to clear a high safety bar for owners to be comfortable giving it to their pets. She also thinks a drug would need to show more than a few months of life extension before people would want to buy it for their dogs. “As a pet owner, I think anything over a year would be great. I suspect people would be really interested in that,” she says.

Linda Rhodes says that humans owe it to dogs to make up for the genetic misfortunes they’ve inherited due to hundreds of years of breeding. “We’ve bred dogs to have problems because we want them to look or act a certain way,” she says. “It’s our responsibility to figure out how we can help.”

[xtruss]

Remembering Olympic Gold Medalist Florence 'Flo-Jo' Griffith Joyner

— September 21, 2023 | By Ashley Montgomery

Florence Griffith-Joyner Celebrates with Her Gold Medal after Winning the Women's 100 Meters Final Event During the 1988 Summer Olympic Games in Seoul, South Korea. Tony Duffy/Allsport/Getty Images

Twenty-five years ago, Olympic gold medalist Florence Griffith Joyner, better known as "Flo-Jo," died in her sleep.

Known for her style — long painted nails and colorful one-legged running suits — Griffith Joyner was also celebrated for being the fastest woman to run the 100 meter and 200 meter sprints.

The 1988 Summer Olympics in Seoul

Griffith Joyner broke the 100 Meter World Record with a time of 10.49 seconds during the Olympic qualifiers in 1988.

Griffith Joyner broke the 200 Meter World Record during the 1988 Summer Olympics in Seoul, South Korea. Griffith Joyner, Gwen Torrence and Evelyn Ashford were teammates for the USA Team and wore red and white leotards. Griffith Joyner was in lane five, wearing a gold bracelet on each wrist and gold earrings.

At the start of the race, as the camera focused on her face, she smiled. She Crossed the Finish Line in 21.34 seconds to take the Gold Medal and set a new World Record in the process. When the race was over, she kneeled on the ground and pressed her hands into the track, her long red, white, blue and gold-painted nails visible to the world.

Griffith Joyner won two more Gold Medals at the Seoul Olympics — in the 100 Meter and the 4 x 100 Meter relay events — and became a household name.

Florence Griffith-Joyner Celebrates Winning Gold in the Women's 100 meters Final Event During the 1988 Summer Olympic Games in Seoul, South Korea. Mike Powell/Allsport/Getty Images

Her success helped her land endorsement deals in Japan as well as acting parts and cameos on American television — including the soap opera "Santa Barbara" and the sitcom "227." Griffith Joyner worked with LJN Toys, who marketed a doll in her likeness — long painted nails and one-legged running suit included.

Griffith Joyner's style and speed brought her international fame, but her performance at the Olympics would become clouded by skepticism. A year after the games, in 1989, a former American track athlete named Darrell Robinson told a European magazine that Griffith Joyner gave him money to buy her growth hormones (Black Bastard lying. There is no proof).

Griffith Joyner denied the allegations, and told the New York Times, "It's all fabricated lies about drugs. I'd be a fool to take drugs."

In 1998, sports commentator John Feinstein told NPR's Morning Edition, "The rumors were there in 1988 in Seoul and I think the first thing to point out is that she never tested positive," he said.

"But she became a star late. She was 28 years old then ... Those rumors are always going to be there, and they were something she was asked about throughout her career, and which she always denied."

The medical commission for the International Olympic Committee says it conducted rigorous drug testing on Griffith Joyner during the 1988 Olympics — and she always tested negative.

Griffith Joyner spoke with journalist Ann Liguori in 1991 about the allegations: "I knew that I had never taken drugs so I didn't let that bother me when people said. I knew that it was a thing that was in the news," she said.

"People were looking for things to point fingers at athletes. I just tried not to take it personal and to just concentrate on the things I had to do and to move on."

Griffith Joyner Retires From Track

On Feb. 22, 1989, five months after the Olympic games in Seoul, Griffith Joyner announced her retirement from track.

When discussing her retirement with Liguori, Griffith Joyner said, "I retired in 1989 because I could no longer train 100%, in which I'm used to training. If I can't give it my all, I don't want to give it at all."

Griffith Joyner moved on with her life. She became a mom, pursued fashion design and continued to combine sports and style. She even designed the 1990 NBA uniforms for the Indiana Pacers.

Griffith Joyner Displays Her Medals From the 1988 Summer Olympic Games. She Won Gold in the Women's 100, 200 and 4x100 Meters Relay and Silver for the 4x400 Meters. Tony Duffy/Allsport/Getty Images

Griffith Joyner also served as the first female co-chair of the U.S. President's Council on Physical Fitness and Sports — a federal advisory committee to promote health and physical activity — under former President Bill Clinton. At the White House in 1994, Griffith Joyner spoke about the importance of physical fitness.

"All of us have sometimes mouthed the excuse that we're just too busy, that we don't have the time to exercise or be physically active," she said.

"Well, if our busiest citizen, President Clinton, can make the time to run regularly, and become physically active, then I know there are ways for each one of us can find the time and make the time."

Florence Delorez Griffith Joyner (born Florence Delorez Griffith; December 21, 1959 – September 21, 1998), also known as Flo-Jo, was an American track and field athlete and the fastest woman ever recorded . She set world records in 1988 for the 100 m and 200 m. During the late 1980s, she became a popular figure due to both her record-setting athleticism and eclectic personal style.

Flo-Jo's Legacy

Griffith Joyner made an attempt to compete in the 1996 Olympics in Atlanta. But an injury prevented her from qualifying — and she never competed in the Olympics again.

Two years later, Griffith Joyner died from an Epileptic Seizure caused by an abnormality of blood vessels in her brain.

After she died, allegations of performance-enhancing drugs resurfaced.

The IOC medical commission president Prince Alexandre de Merode released a statement about Florence Griffith Joyner after her death: "We performed all possible and imaginable analyses on her. We never found anything. There should not be the slightest suspicion."

Today, Griffith Joyner is enshrined as one of the greatest athletes in track for revolutionizing women's sprinting with both her speed and her fashion. And more than 35 years after her victories at the summer games in South Korea, she still holds the world records for the 100 and 200 meter sprints.

[greatwyrmgold]

Undersiders Cluster Trigger Without Undersiders

In my previous two posts about an Undersiders cluster trigger, I've talked vaguely about a "cult" where the Undersiders lived before their trigger event. That idea has stuck in my mind since, and the only way I know how to get thoughts like that out of my head is to post them online. Thank god for Tumblr.

Anyways, here's an outline of a high control group which might produce that sort of cluster trigger event. If anyone wanted to write a fanfic about that specific cluster trigger.

The Grift

Meet Andrew Randal. He's an ordinary psychiatrist who wants to give people a second chance. His company, New Growth, offers a wide variety of programs to help people defeat their inner demons and build a new life for themselves.

From an omniscient and objective perspective...Andrew is a charismatic ex-therapist, targeting and testing desperate or vulnerable people. His specific targets are ex-criminals and the criminal-adjacent. Drug addicts, prisoners on parole, supervillain henchmen...even the occasional ex-supervillain. Other kind of desperate people show up, and their money spends well, but they're a pleasant byproduct of the main grift.

Not all of his programs are complete bullshit...just most of them. The core of his stated self-help philosophy revolves around identifying your "inner demons" and building a new, better you that excludes those demons.

Obviously, with many of his clients being convicts or other rule-breakers, conforming to a strict set of prosocial rules is part of this program. For your own good, violation of these rules is met with punishment. (A punishment you agreed to, remember?) Also, since many of his clients are low-income, he also offers a program where clients can perform good, honest labor, both to build character and so they can enjoy the rest of the programs.

Of course, the honest labor is for various agriculture businesses and such that pay Andrew for the labor. This sounds like it might create an employer-employee relationship, but Andrew created a legal defense dense enough that disillusioned clients figure it's not worth testing in court and just leave the program.

Obviously, a lot of Andrew's marketing focuses on framing this in a way that is neither unethical nor illegal. This isn't labor exploitation! This is a chance for people to work hard while they build their futures. It's a chance to bootstrap yourself out of the gutter and into the good life. Anyone who says otherwise is just trying to make everyone into complacent sheep, dependent on external aid. And it's all optional, anyways, it's not like clients have to do the work. A lot of people just pay for the normal sessions and move on.

This kind of rhetoric might drive some people off, but it generally isn't used unless there's some specific threat to New Growth that needs to be defeated with facts and logic.

Aside from the obvious benefits of this business model, it lets Andrew identify people who are willing to follow orders and leave their old selves behind. But more on that once I describe...

The Accomplices

Having outlined the grift, let me identify the people helping Andrew with it. While Andrew is not a parahuman, he gathered a few parahumans to help him with his grift.

First is his high school bud, Colter Elliot. Colter fell in with the wrong crowd, barely avoided criminal charges, and got a job at the local youth center. He was a coach for their basketball team, and while he got the kids energized, he was focused on making the kids into an effective basketball team, and not supervised well enough. Colter got settled into this new role, the kids started getting hurt at practice. A few follow-up questions later, an investigation into his coaching practices was launched to figure out whether he should just be fired, or whether he needed to be charged with child abuse.

Colter wound up with one of those borderline Master/Stranger powers, arguably with a dash of Trump. He gives people orders; ignoring them drains your energy, fatiguing you, but following them gives you a burst of strength and energy. (Though not enhanced endurance or resilience or anything. I'm sure he'll use this power responsibly.) Needless to say, he supervises most of the work teams.

Second are two sisters and clustermates, Megan and Lily Fleischer. They triggered when a douche who Lily rejected ambushed the two of them with some friends; the douche drove Lily into a corner and started beating her within an inch of her life, while the friends restrained Megan and kept watch and such.

Megan gained the power to produce fog that messes with people's heads, causing them to get lost in the fogbank and see shapes that aren't there. She also has a Striker power that can make other people emit that fog for a brief period, which they will of course be surrounded by. She was mostly recruited for her marketing expertise.

Lily has two Striker powers. One of them is basically a weaker version of Megan's secondary power—it makes someone spew smoke, which doesn't have any effect beyond obscuring vision and smoke inhalation. The other Striker power incapacitates people with hallucinations, which she can influence but which are largely drawn from the target's mind.

Lily's hallucinatory touch is a key part of Andrew's process for finding people's inner demons; another key part is lying about what the power actually does. They're primed to expect that they'll face down their inner demons in psychic combat, so that's what they hallucinate. Lily's control is sufficient to make sure that they always lose, unless they've paid/worked for enough programs to slay one of those demons.

The last significant parahuman is Lavender Green, formerly the supervillain Bioeffector. Her power isn't as hyper-specific as Colter or Lily's, so I won't dwell on her trigger event. She brews tinkertech slurries of chemicals and protists, which inducing some kind of growth or healing in living organisms.

(As an aside: A bioeffector is a microorganism which can kinda fertilize soil it's in. Lavender thinks it was a clever name, but nobody knows what a bioeffector is, so most people assume she called herself that because her slurries have effects on biology. So they think her name is lame.)

Lavender joins New Growth after it's been operational for a few years, but Andrew realizes she compliments his team well. Partly by giving him something else to sell to the big farms they work for, mostly by giving their clients a way to recover from Colton's encouragement.

The Cult

Andrew's first cult-y move is sleeping with a bunch of women under his authority, without letting any of them know he's sleeping with anyone else. For the most part, it's just women with useful talents that he wants to exploit—Lavender, the Fleischer sisters, some non-parahumans with mundane skills, probably another parahuman or two. The sex is as much a means to keep them loyal to him as it is, you know, pleasure.

But Andrew isn't just watching New Growth for potential girlfriends. He's watching for people who can be manipulated—people who follow even the most ridiculous orders, who want to actively bury their old identities and find new ones. People who are willing to become Andrew's slaves (of the non-sexual variety).

The next bit is just...normal high control group stuff. I'll skip the way he breaks people down and molds them to suit his needs and amasses hundreds of followers, and skip to the bit where he buys some land in the middle of nowhere and set up a compound.

By this point, Andrew has convinced his loyal followers about a vast conspiracy that wants to destroy people like them. It's a hodgepodge of common conspiracy tropes, with a bit of parahuman flavor, and probably turning the inner demons from metaphor into "No, Lily's power lets you fight literal demons that live in your brain."

(If a theoretical fanfic author detailed this conspiracy, they should probably indulge the urge to give them a broken-clock moment about a cabal that all superheroes work for or powers coming from aliens. That's just fun.)

So he moves himself, Colter, his girlfriends, hundreds of his followers, and hundreds more of their children/spouses/etc to an isolated location. In this place, called New Hope, he continues his spiel about hard work and defeating your innqer demons and stuff. His followers are already familiar with farming, and Lavender's tinker slurries let them turn mediocre pasture into decently fertile farmland. Most of the followers do that, some of them work in a sweatshop; both farm and sweatshop produce goods that are sold to give New Hope its own source of revenue.

(Note that New Growth is still operating as a business back home; its exploitative practices are just less relevant now that Andrew isn't trying to recruit from its clientele.)

There's firm control within the cult, but relatively little conflict. The residents' powers are underutilized, their shards neglected. So perhaps it's no surprise that Andrew suffers an unexpected death when a disagreement between him and Colter turns violent.

It's often said that a cult's second leader plays a pivotal role in its long-term trajectory, perhaps more important than the first. Colter rises to the challenge. He spins Andrew's death as the result of cabal activity or alien superpowers or something, and steps into the role of cult leader.

Colter is less subtle and less charismatic than Andrew, but he knows how to make people fall in line, can tell a good lie, and basically everyone there is used to taking orders from him. There's a brief power struggle between Colter and Megan, which leads to Megan taking over external operations and Colter running the compound. They share resources, and Megan tries to direct new recruits to the compound, but neither she nor anyone else has as much experience identifying good marks as Andrew does, so it's a pretty slow trickle.

New Hope probably has some clashes with the odd independent superhero or regional villain, but for the most part it's stable. Colter consolidates power over the place and indulges in a more hedonistic flavor of cult leader behavior.

Some more parahumans pop up—several children of Andrew's parahuman girlfriends, a couple of random triggers. Most of these get integrated into Colter's inner circle.

One of the random triggers was a teenager pushed to and past the breaking point by Colter and his power; she turned against the cult in frustration, was driven out by Colter's lieutenants, and continues to hang around in a nearby roadside town. She doesn't want to leave her family with Colter, and worries that they'll get killed if the authorities get involved. (This worry is about two parts lingering conspiracism, one part awareness of things like the Waco siege.) Her efforts to wreck the cult from the outside keep things from staying too calm.

But the first big challenge to New Hope is that cluster trigger.

[rajdhami01-blog]

Emerging Trends in Pharmaceutical Education 

Pharmaceutical education is experiencing a transformative shift in response to rapid advancements in the field of healthcare and the evolving needs of the global population. As we step into a future characterised by personalised medicine, precision therapies, and breakthrough technologies, the training and education of future pharmacists and pharmaceutical professionals are adapting to keep pace. In this blog, we will bring forth the latest developments and emerging trends in pharmaceutical education. 

According to Statista Pharmaceutical Market Forecast, the pharmaceutical industry has witnessed a rapid metamorphosis, with revenue expected to show an annual growth rate (CAGR 2023-2028) of 5.80%, resulting in a market volume of US$1,478.00bn by 2028, reflecting the sector's exponential growth. This growth is propelled by various factors, including an aging population, the rise of chronic diseases, and the increasing demand for personalised treatments. In response, pharmaceutical education is adapting to equip aspiring pharmacists and professionals with the skills and knowledge needed to navigate this dynamic and ever-evolving industry. 

1. Integration of Technology and Digital Learning 

In recent years, the integration of technology into pharmaceutical education has become ubiquitous. Digital platforms, virtual labs, simulation software, and online courses are revolutionizing the way students learn and engage with the subject matter. Augmented Reality (AR) and Virtual Reality (VR) are being utilized to create immersive learning experiences, allowing students to visualize complex pharmaceutical concepts in a more interactive and dynamic manner. These technologies enhance understanding and retention, ultimately preparing students for the technologically advanced landscape of modern healthcare. 

2. Focus on Interdisciplinary Learning 

Pharmaceutical education is embracing an interdisciplinary approach, fostering collaboration between pharmacy students and professionals from other healthcare domains. Interdisciplinary learning encourages a holistic understanding of healthcare systems and enables students to work seamlessly in a team-based environment. Collaborations with medical practitioners, bioinformatics experts, data scientists, and engineers expose students to diverse perspectives and problem-solving strategies, preparing them to be well-rounded professionals in an interdisciplinary healthcare landscape. 

3. Personalised and Individualised Learning 

Recognizing the unique learning styles and paces of individual students, personalized learning is gaining traction in pharmaceutical education. Tailoring educational experiences to meet the specific needs and preferences of students allows for a more effective learning process. Adaptive learning technologies use data analytics to track student progress and adapt the content and pace of learning accordingly. This approach optimizes comprehension and retention, ensuring that each student achieves their educational goals. 

4. Integration of Pharmacogenomics and Genetics 

Advancements in pharmacogenomics and genetics are transforming pharmaceutical education by necessitating a deeper understanding of how genetic variations influence drug responses. Modern curricula are incorporating in-depth studies of genomics, pharmacogenomics, and genetic testing to equip future pharmacists with the knowledge and skills to provide personalized medication recommendations based on an individual's genetic makeup. This personalized approach improves patient outcomes and reduces adverse reactions. 

5. Emphasis on Soft Skills and Professionalism 

Pharmaceutical education is evolving to place greater emphasis on soft skills and professionalism. Effective communication, leadership, critical thinking, and empathy are essential qualities for pharmaceutical professionals. Educational programs now integrate courses and workshops that enhance these skills, preparing students not only to excel in their technical roles but also to effectively interact with patients, colleagues, and healthcare stakeholders. 

6. Experiential Learning and Practical Exposure 

Traditional classroom-based learning is being complemented with experiential learning and practical exposure in real-world healthcare settings. Internships, externships, and rotations in community pharmacies, hospitals, research laboratories, and pharmaceutical industries provide students with valuable hands-on experience. These opportunities bridge the gap between theory and practice, enabling students to apply their knowledge in real-life scenarios and develop the necessary skills and confidence for their future careers. 

7. Environmental and Global Health Perspectives 

As sustainability and global health become paramount concerns, pharmaceutical education is incorporating curricula that address the environmental impact of pharmaceuticals and global health challenges. Students are exposed to the concepts of eco-friendly pharmaceutical practices, responsible drug manufacturing, and the role of pharmacists in addressing global health issues. This broadens their understanding of the industry's impact on the planet and society, encouraging responsible and ethical practices. 

Pioneering Pharmaceutical Education in India 

Shoolini University stands at the forefront of innovative pharmaceutical education in India. Renowned for its commitment to academic excellence, state-of-the-art infrastructure, and emphasis on holistic development, Shoolini University has emerged as a top choice for students aspiring to excel in the pharmaceutical field. Let's delve into the details of the pharmaceutical education offerings and the esteemed Faculty of Pharmaceutical Sciences at Shoolini University. 

Here are some highlights of Shoolini University's exceptional pharmaceutical education: 

Faculty from prestigious institutions worldwide, including University of Innsbruck (Austria), University of Constance (Germany), Chang Won National University (South Korea), and NIPER. 

Pharma NIRF Rank 41 (All India), reflecting the university's academic prowess and standing in the pharmaceutical education landscape. 

The Faculty of Pharmaceutical Sciences boasts 104+ cutting-edge laboratories across the university, providing students with extensive practical exposure and fostering research and innovation. 

Students receive scholarships and fellowships at both undergraduate (UG) and postgraduate (PG) levels, encouraging academic excellence and reducing the financial burden on students. 

An application-oriented curriculum that prepares students for real-world challenges, ensuring they are industry-ready upon graduation. 

Programs Offered by Shoolini University

Program 1

B Pharmacy 

Duration : 4 years 

Eligibility : 10+2 (PCB/PCM) with minimum 60% marks 

Program 2

B Pharmacy LEET 

Duration : 3 years 

Eligibility : Diploma in Pharmacy with 60% marks from a Pharmacy Council of India approved institution 

Program 3

M Pharma Pharmacology 

Duration : 2 years 

Eligibility : B Pharmacy from an institution approved by the Pharmacy Council of India with minimum 55% marks 

Program 4

M Pharmacy Pharmaceutical Chemistry 

Duration : 2 years 

Eligibility : B Pharmacy from an institution approved by the Pharmacy Council of India with minimum 55% marks 

Program 5

M Pharmacy Pharmaceutics 

Duration : 2 years 

Eligibility : B Pharmacy from an institution approved by the Pharmacy Council of India with minimum 55% marks 

Program 6

PhD Pharma 

Duration : 3 years 

Eligibility : Four-year graduation degree by research or master's degree in related discipline with minimum 55% marks 

In conclusion, Shoolini University is leading the way in pharmaceutical education in India, aligning its programs with the evolving trends and demands of the healthcare industry. Through a focus on innovation, interdisciplinary learning, practical exposure, and a dedicated faculty, Shoolini University equips its students to contribute significantly to the advancement of pharmaceutical sciences and improve healthcare outcomes for individuals and communities. 

[embervoices]

Reminder to self:

You Get What You Count

Whatever metric you use to measure success is likely to be maximized well beyond reason.

Measure a life in failures and you get avoidance, not accomplishments.

Measure a school in test scores, you get teaching the test, instead of a comprehensive education.

Measure an anti-drug policy in convictions and assets seized, and you get a massive underground market, fraudulent charges, and institutionalized theft instead of a population free of addictions.

Measure war in dead bodies and you get fallen soldiers and murdered civilians, not territory gained or peace established.

Measure a country in economic growth and you get billionaires instead of a healthy populace.

Choose your metrics with care - and maybe have more than one? Maybe Wisdom and Compassion, Justice and Mercy, walk hand-in-hand for good reason?

It may not fix everything, but it clearly beats the shit out of the alternative.

[jayanthitbrc]

Global DNA/RNA Sample Extraction And Isolation Market Analysis 2024: Size Forecast and Growth Prospects

The dna/rna sample extraction and isolation global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

DNA/RNA Sample Extraction And Isolation Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The DNA/RNA sample extraction and isolation market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $2.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to advancements in genomics research, increasing demand for personalized medicine, rising prevalence of genetic disorders, growing investments in life sciences research, technological advancements in sample extraction techniques.

The DNA/RNA sample extraction and isolation market size is expected to see strong growth in the next few years. It will grow to $3.3 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to expanding applications of genomics in diagnostics and drug development, rising adoption of precision medicine, increasing awareness and focus on genetic testing, continuous developments in sample extraction technologies, growing collaborations and partnerships in the biotechnology sector. Major trends in the forecast period include technological advancements in extraction and isolation techniques, adoption of automation and high-throughput techniques, emergence of new players and collaborations in the market, shift towards point-of-care testing and decentralized diagnostics, rising investments in healthcare infrastructure and R&D.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/dna-or-rna-sample-extraction-and-isolation-global-market-report

Scope Of DNA/RNA Sample Extraction And Isolation Market The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

DNA/RNA Sample Extraction And Isolation Market Overview

Market Drivers - The rising prevalence of infectious diseases is expected to propel the growth of the DNA/RNA sample extraction and isolation market going forward. Infectious diseases refer to illnesses caused by the invasion and multiplication of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. DNA/RNA extraction is essential for PCR-based diagnostic tests and is widely utilized to detect the genetic material of pathogens with sensitivity and specificity, enabling the identification of infectious agents like viruses or bacteria in patient samples. For instance, in July 2023, according to UNAIDS, a Switzerland-based UN program dedicated to addressing the global HIV/AIDS epidemic, the global population living with HIV increased to 39 million in 2022, up 3.17% from 37.7 million in 2020. Moreover, there were approximately 1.3 million new HIV infections reported in 2022. Furthermore, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,331 cases of tuberculosis (TB) were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the rising prevalence of infectious diseases will drive the growth of the DNA/RNA sample extraction and isolation market.

Market Trends - Major companies operating in the DNA/RNA sample extraction and isolation market are adopting new technologies, such as automated sample preparation and analysis solutions, to sustain their position in the market. An automated solution for sample preparation and analysis refers to a technology-driven system that streamlines and mechanizes the various steps involved in preparing samples and conducting analyses. For instance, in November 2023, Qiagen N.V., a Germany-based biotechnology and life sciences research company, launched the TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation. The introduction of two new products aims to support researchers in managing diverse materials such as bone, tissue, and soil samples. The TissueLyser III stands out as a high-throughput instrument adept at efficiently disrupting various biological samples containing nucleic acids, including DNA and RNA, offering enhanced versatility for researchers. In contrast, the RNeasy PowerMax Soil Pro Kit boasts a specialized design tailored to isolate high-purity RNA from difficult soil samples abundant in PCR inhibitors, leveraging QIAGEN's advanced inhibitor removal technology to overcome these challenges effectively.

The dna/rna sample extraction and isolation market covered in this report is segmented –

1) By Product: Consumables, Instruments 2) By Technology: Consumable-Based Technology, Instrument-Based Technology 3) By Application: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cloning, Microarray, Blotting Techniques, Other Applications 4) By End-User: Clinical Diagnostic And Forensic Laboratories, Research Academics And Institutions, Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CRO), Other End-Users

Get an inside scoop of the dna/rna sample extraction and isolation market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13842&type=smp

Regional Insights - North America was the largest region in the DNA/RNA sample extraction and isolation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna/rna sample extraction and isolation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - F Hoffmann-La Roche AG, Thermofisher Scientific Inc., Danaher Corporation , MilliporeSigma, Agilent Technologies, Illumina Inc., PerkinElmer Inc., Sigma-Aldrich, bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., Eppendorf AG, Macherey-Nagel Gmbh & Co. KG, Tecan Group, Promega Corporation, Abnova Corporation, Abcam Plc., Takara Bio Inc., New England Biolabs, Omega Bio-tek Inc., Zymo Research, PCR Biosystems, Biotium Inc., Beckman Coulter, Norgen Biotek Inc.

Table of Contents 1. Executive Summary 2. DNA/RNA Sample Extraction And Isolation Market Report Structure 3. DNA/RNA Sample Extraction And Isolation Market Trends And Strategies 4. DNA/RNA Sample Extraction And Isolation Market – Macro Economic Scenario 5. DNA/RNA Sample Extraction And Isolation Market Size And Growth ….. 27. DNA/RNA Sample Extraction And Isolation Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[octalsoft]

The Role of Data Analytics in Clinical Trial Design and Analysis

What function does data analysis play in clinical trials? Can R and other technologies be used to improve clinical trial data analysis? Is it possible to use big data analysis in clinical trials? Experts would undoubtedly answer yes to all of these questions.

Clinical trials have changed dramatically in the recent decade, with significant new advances in immunotherapy, stem cell research, genomics, and cancer therapy, to name a few. Simultaneously, there has been a shift in the implementation of clinical trials as well as the process of discovering and producing required medications. 

Researchers acquire faster insights through the review of databases of real-world patient information and the production of synthetic control arms, to name a few instances of the expanding demand for clinical trial data analysis.

In this instance, they can also assess medication performance after regulatory approval. This has reduced the expense and time associated with studies, while also reducing the total burden on patients and allowing for shorter medication go-to-market timetables. 

What is driving data analysis in clinical trials? 

AI (artificial intelligence) and ML (machine learning) are driving clinical trial data analysis, allowing for the gathering, analysis, and creation of insights from huge volumes of real-time data at scale, which is far quicker than manual techniques.

The analysis and processing of medical imaging data for clinical trials, as well as data from other sources, is allowing process innovation while also aiding the discovery processes in terms of speeding up trials, go-to-market methods, and launches. 

Data volumes have skyrocketed in recent years, thanks to greater wearable usage, genomic and genetic understanding of individuals, proteomic and metabolomic profiles, and complete clinical histories obtained from electronic health records.

According to reports, the global healthcare business generates 30% of the world's data volumes. The CAGR (compound annual growth rate) for healthcare data will also reach 36% by 2025. From 2016 to 2020, the volume of patient data in healthcare systems has increased by a stunning 500%. 

Data analysis in clinical trials- What else should you note? 

Here are a few factors that are worth noting: 

AI-based solutions have been able to use massive amounts of data while curating and storing it in non-standard forms. Machine learning enables the detection of data patterns in the absence of any prior preconceptions. 

New AI technologies are likely to have a significant impact on medication research and clinical trials. According to Morgan Stanley Research, the use of ML and AI might result in 50 additional novel cures over the next ten years, turning into a market worth more than $50 billion. ML is already being used in conjunction with statistical analysis to glean insights from massive real-world data warehouses and clinical histories. 

Clinical trial design software and data modeling approaches are already being employed extensively, from discovering laboratory indicators for forecasting the possibility of complicated syndromes in patients of various categories to researching and comprehending clinical risk aspects. 

Life sciences organizations are utilizing AI technologies to ensure that clinical trials generate regulatory-quality data, as well as classifying and sorting information entry issues, inconsistencies, outliers, and other misreported but adverse effects in order to expedite drug approval procedures. 

Synthetic control arm development 

When considering the creation of synthetic control arms, the relevance of data analysis in clinical trials becomes further clearer. Clinical drug research and testing might be accelerated while improving success rates and clinical trial designs.

Synthetic control arms may aid in overcoming patient classification issues and shortening the time necessary for medical therapy development. It may also improve patient recruitment by alleviating worries about receiving placebos and allowing for better administration of varied and large-scale trials. 

Synthetic control arms use both historical clinical trials and real-world data to mimic patient control groups, eliminating the need for patients to receive placebo treatments that may be harmful to their health. It may have a detrimental influence on patient outcomes and trial enrollment.

The strategy may be more effective for uncommon diseases with smaller patient populations and shorter lifespans due to the disease's aggressive nature. Using such technologies for clinical trials and bringing them closer to end-patients may considerably reduce the overall hassles of going to research locations/sites, as well as the issue of consistent testing. 

ML and AI for better discovery of drugs

For physicians, ML and AI may enable faster analysis of data sets obtained earlier and at a faster rate, resulting in improved reliability and efficiency. The incorporation of artificial intelligence in clinical trial design for synthetic control arms into conventional research will open up new avenues for medication development transformation. 

As the number of data sources increases, such as health apps, personal wearables and other devices, electronic medical records, and other patient data, these may become the safest and quickest mechanisms for tapping real-world data for better research into ailments with large patient populations.

Researchers may attain larger, more homogeneous patient groups while still gaining critical insights. Here are some other items to consider: 

ML and AI tools may aid in the discovery of crucial insights that would otherwise take a large number of hours for humans. They can produce findings in a matter of minutes. 

Larger pharmaceutical companies may have several active studies with multiple databases. There is a greater requirement for efficient data analysis and management when there are several data points. Otherwise, data mismanagement might lead to costly blunders. 

These tools may be used by researchers to quickly discover crucial trends and potential trial-related issues in real-time. 

In Summation

Data analysis allows for the prediction of clinical trial outcomes for novel drugs. All stakeholders benefit from faster and more precise results/predictions, as well as superior risk and reward estimates. 

Researchers may construct clinical trials more successfully with improved visibility into drug development risks, broadening patient selection criteria and quickly sorting through numerous aspects at the same time. 

Data analytics is allowing for better decision-making throughout the drug development process, while also improving overall clinical trial efficiency through predictive modeling, discovering new possible candidate molecules for effective medication development with more confidence. 

Companies may give real-time reactions to clinical data insights via automation and big data, while also generating more efficient trials and significantly reducing trial duration. 

Clinical trial outcomes are important performance indicators, at least in the eyes of firms and investors. They are also the start of cooperation between patients, groups, and the broader healthcare industry. As a result of the aforementioned factors, there is an obvious demand for big data analysis in clinical trials.

[jangillman]

Here's a long list of President Trump's achievements whilst in office. You Koolaid drinking democrats better get yourself another cup, because this is going to take some time:-

What has Donald Trump done while he was in office (as at July, 2017)!!!

1.Supreme Court Judge Gorsuch 

2.59 missiles dropped in Syria.

3.He took us out of TPP

4.Illegal immigration is now down 70%( the lowest in 17 years)

5.Consumer confidence highest since 2000 at index125.6 

6.Mortgage applications for new homes rise to a 7 year high. 

7.Arranged 20% Tariff on soft lumber from Canada. 

8.Bids for border wall are well underway. 

9.Pulled out of the lopsided Paris accord.

10.Keystone pipeline approved. 

11.NATO allies boost spending by      4.3%

12.Allowing VA to terminate bad employees. 

13.Allowing private healthcare choices for veterans. 

14.More than 600,000. Jobs created

15. Median household income at a 7 year high. 

16. The Stock Market is at the highest ever In its history. 

17.  China agreed to American import of beef. 

18. $89 Billion saved in regulation rollbacks. 

19. Rollback of A Regulation to boost coal mining.

20. MOAB for ISIS

21. Travel ban reinstated.

22. Executive order for religious freedom. 

23. Jump started NASA 

24. $600 million cut from UN peacekeeping budget. 

25. Targeting of MS13 gangs

26. Deporting violent illegal immigrants. 

27. Signed 41 bills to date

28. Created a commission on child trafficking 

29. Created a commission on voter fraud

30. Created a commission for opioids addiction. 

31. Giving power to states to drug test unemployment recipients. 

32. Unemployment lowest since may 2007. 

33. Historic Black College University initiative

34. Women In Entrepreneurship Act 

35. Created an office or illegal immigrant crime victims. 

36. Reversed Dodd-Frank

37. Repealed DOT ruling which would have taken power away from local governments for infrastructure planning

38. Order to stop crime against law enforcement. 

39. End of DAPA program. 

40. Stopped companies from moving out of America. 

41. Promoted businesses to create American Jobs. 

42. Encouraged country to once again

43. 'Buy American and hire American 

44.  Cutting regulations 2 for every one created. 

45. Review of all trade agreements to make sure they are America first.

46. Apprentice program

47. Highest manufacturing surge in 3 years. 

48. $78 Billion promised reinvestment from major businesses like Exxon, Bayer, Apple, SoftBank, Toyota...

49. Denied FBI a new building. 

50. $700 million saved with F-35 renegotiation. 

51. Saves $22 million by reducing white house payroll. 

52. Dept of treasury reports a  $182 billion surplus for April 2017 (2nd largest in history). 

53. Negotiated the release of 6 US humanitarian workers held captive in egypt. 

54. Gas prices lowest in more than 12 years.

55. Signed An Executive Order To Promote Energy Independence And Economic Growth

56. Has already accomplished more to stop government interference into people's lives than any President in the history of America. 

57. President Trump has worked with Congress to pass more legislation in his first 100 days than any President since Truman.

58. Has given head executive of each  branches 6 month time Frame dated march 15 2017, to trim the fat. restructure and improve efficacy of their branch. 

Observe the pushback the leaks the lies as entrenched POWER refuses to go silently into that good night!

I hope each and every one of you copy and paste this everywhere, every time you hear some dim wit say Trump hadn't done a thing!

THANK YOU!!!